Hanall Biopharma Co.,Ltd
KSC: 009420.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sean Jeong
- Employees
- 309
- Headquarters
- Daejeon, South Korea
- IPO year
- 2000
- Market cap
- ₩2.2T
- Website
- https://www.hanall.co.kr
Loading 009420…
Loading profile data…Frequently asked questions about 009420
What does Hanall Biopharma Co.,Ltd (009420.KS) do?
Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atheroscl...
Where does 009420.KS trade?
Hanall Biopharma Co.,Ltd (009420.KS) trades on the Korea Exchange.
What sector is 009420.KS in?
Hanall Biopharma Co.,Ltd (009420.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hanall Biopharma Co.,Ltd?
Sean Jeong is the chief executive officer of Hanall Biopharma Co.,Ltd (009420.KS).
Where is Hanall Biopharma Co.,Ltd headquartered?
Hanall Biopharma Co.,Ltd is headquartered in South Korea.
Does 009420.KS pay a dividend?
Hanall Biopharma Co.,Ltd (009420.KS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 009420.KS go public?
Hanall Biopharma Co.,Ltd (009420.KS) completed its initial public offering in 2000.